Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced HER2-Negative Breast Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07523529
What this trial is testing

Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

Who this might be right for
Advanced UnresectableMetastatic
Beijing Biotech 72
Testing effectiveness (Phase 2)Looking for participantsNCT07510802
What this trial is testing

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

Who this might be right for
Breast Cancer (Advanced/Metastatic)HER2-positive Breast CancerTriple-negative Breast Cancer
Beijing Biotech 60
Early research (Phase 1)UnknownNCT05337657
What this trial is testing

A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Genor Biopharma Co., Ltd. 10
Testing effectiveness (Phase 2)Study completedNCT03394027
What this trial is testing

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Who this might be right for
Triple Negative Breast CancerEndometrial CancerHormone Receptor Positive, HER2 Negative Breast Cancer
National Cancer Institute (NCI) 30
Testing effectiveness (Phase 2)Study completedNCT01151046
What this trial is testing

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Who this might be right for
Her2 Negative Breast Cancer Patients
Merrimack Pharmaceuticals 118
Early research (Phase 1)Looking for participantsNCT05098210
What this trial is testing

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Cutaneous Melanoma+22 more
Fred Hutchinson Cancer Center 28
Early research (Phase 1)Active Not RecruitingNCT06299124
What this trial is testing

A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors

Who this might be right for
Breast CancerAdvanced Solid Tumor
Regor Pharmaceuticals Inc. 40
Large-scale testing (Phase 3)Active Not RecruitingNCT05346224
What this trial is testing

Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmsHER2-positive Breast Cancer
Shanghai Henlius Biotech 900
Testing effectiveness (Phase 2)Study completedNCT04796623
What this trial is testing

TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Who this might be right for
HR-positive, HER2-negative Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 122
Testing effectiveness (Phase 2)Study completedNCT01520103
What this trial is testing

Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer

Who this might be right for
Her2-negative Metastatic Breast CancerHer2-negative Locally Advanced Breast Cancer
AIO-Studien-gGmbH 139
Testing effectiveness (Phase 2)Looking for participantsNCT06705127
What this trial is testing

Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.

Who this might be right for
HR-positive,HER2-negative Breast Cancer
First Affiliated Hospital of Zhejiang University 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07151586
What this trial is testing

Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsNeoplasm MetastasisHER 2 Low-expressing Breast Cancer
UNICANCER 260
Testing effectiveness (Phase 2)Looking for participantsNCT06950086
What this trial is testing

Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors

Who this might be right for
HR-positive, HER2-negative Advanced Breast Cancer
TYK Medicines, Inc 180
Testing effectiveness (Phase 2)Study completedNCT03839823
What this trial is testing

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 222
Early research (Phase 1)WithdrawnNCT02567396
What this trial is testing

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Who this might be right for
Estrogen Receptor NegativeHead and Neck Squamous Cell CarcinomaHER2/Neu Negative+20 more
National Cancer Institute (NCI)
Early research (Phase 1)Ended earlyNCT04060862
What this trial is testing

Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 20
Early research (Phase 1)UnknownNCT06172322
What this trial is testing

A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer

Who this might be right for
HR Positive/HER-2 Negative Breast Cancer
Nanjing Chia-tai Tianqing Pharmaceutical 42
Testing effectiveness (Phase 2)Active Not RecruitingNCT05810870
What this trial is testing

PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin

Who this might be right for
Breast CancerAdvanced Breast CancerMetastatic Breast Cancer
MedSIR 14
Not applicableUnknownNCT05334147
What this trial is testing

Anlotinib Combined With Chemotherapy for the Treatment of HER2 Negative Advanced Breast Cancer

Who this might be right for
HER2-negative Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 315
Testing effectiveness (Phase 2)Active Not RecruitingNCT05392608
What this trial is testing

SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)

Who this might be right for
Neoplasm, BreastCongenital, Familial and Genetic Disorders
Borstkanker Onderzoek Groep 130
Next Page